MECLIZINE HYDROCHLORIDE ![]() (mek'li-zeen) ![]() Antivert, Antrizine, Bonamine ![]() Classifications: antihistamine; h1-receptor antagonist; anti-vertigo agent; Therapeutic: antihistamine, h1-receptor antagonist, antivertigo Pregnancy Category: B |
12.5 mg, 25 mg, 50 mg tablets; 25 mg, 30 mg capsules
Long-acting antihistamine, with marked effect in blocking histamine-induced vasopressive response but only slight anticholinergic action. Marked depressant action on labyrinthine excitability and on conduction in vestibular-cerebellar pathways.
Exhibits antivertigo, and antiemetic effects.
Management of nausea, vomiting, and dizziness associated with motion sickness and in vertigo associated with diseases affecting vestibular system.
Hypersensitivity to meclizine; GI obstruction, ileus.
Angle-closure glaucoma, older adults, asthma, prostatic hypertrophy, pregnancy (category B), lactation. Safety in children less than 12 y is not established.
Motion Sickness Adult: PO 2550 mg 1 h before travel, may repeat q24h if necessary for duration of journey Vertigo Adult: PO 25100 mg/d in divided doses |
Assessment & Drug Effects
Patient & Family Education